Shape Therapeutics Unveils AAVid Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery…
Posted: December 3, 2020 at 2:56 pm
SEATTLE--(BUSINESS WIRE)--Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.
The AAVidTM capsid discovery platform uses non-random mutational fitness to create massive capsid libraries of billions of unique AAV variants for direct-to-NHP in vivo biological selection. By combining cutting-edge DNA synthesis, advanced synthetic biology, next-generation sequence barcoding and machine learning algorithms, ShapeTX generates industry-leading library size and diversity to enable the development of best-in-class human therapeutics.
Wildtype first-generation AAVs are enabling the recent advances in gene therapy, but they have been plagued by toxicities in the clinic due in part to a lack of tissue specificity, resulting in the need for high doses. Our AAVidTM platform solves the issue by creating novel capsid variants with specific tissue-tropism, said Francois Vigneault Ph.D., President and CEO at ShapeTX. Weve stayed quiet for the past three years while developing a superior AAV platform technology and are excited to announce that we have best-in-class AAV variants in hand. Today, we are announcing our novel liver-tropic AAV5 variants stay tuned for more to come.
David J. Huss, Ph.D., Vice President and Head of Research added, The vast structural space for exploration at the AAV capsid/target cell interface necessitates enormous library size and diversity, which until now, has only been probed with capsid library sizes in the tens of thousands to millions. At ShapeTX, we set out to create a superior AAV capsid discovery platform with library sizes in the billions of unique variants, thereby maximizing the opportunity for novel virus/target cell interactions. Dr. Huss presented the details of the platform at the 2nd RNA Editing Summit on Dec. 2, 2020.
About Shape Therapeutics, Inc
Shape Therapeutics is a biotechnology company developing next-generation RNA-targeted therapies to treat the worlds most challenging diseases. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfixTM, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVidTM, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Shape Life!
Originally posted here:
Shape Therapeutics Unveils AAVid Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery...
- Advarra Announces New Gene Therapy Ready Site Network - PRNewswire - January 23rd, 2021
- UK biotech Ixaka scores additional funding for cell and gene therapy research - PharmaTimes - January 23rd, 2021
- Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies - Business Wire - January 23rd, 2021
- Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy - BioSpace - January 23rd, 2021
- Cancer Gene Therapy Market Size Study with COVID-19 Impact 2020, Share, Industry Analysis, Growth, Segmentation and Forecast to 2026 KSU | The... - January 23rd, 2021
- Rexgenero relaunches with $54M, new name, focus on cell and gene therapies - BioWorld Online - January 23rd, 2021
- Chinese scientists develop new gene therapy that can delay the aging process - National Post - January 23rd, 2021
- Gene therapy developed to delay ageing - The Financial Express - January 23rd, 2021
- Voyager Therapeutics: Complicated Story In Gene Therapy Development - Seeking Alpha - January 23rd, 2021
- Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook - GlobeNewswire - January 23rd, 2021
- How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division - BioPharma Dive - January 22nd, 2021
- Neurogene in tie up with university to advance gene therapy technologies - BioPharma-Reporter.com - January 22nd, 2021
- Cell and Gene Therapy Consumables Market 2020 Key Manufacturers, Development Trends and Competitive Analysis 2026 KSU | The Sentinel Newspaper - KSU... - January 22nd, 2021
- New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health - January 22nd, 2021
- Lilly Completes Acquisition of Prevail Therapeutics - BioSpace - January 22nd, 2021
- Cancer Gene Therapy Market : Future Prospects With Covid-19 Impact Analysis 2027 | Top Players- Adaptimmune, GlaxoSmithKline plc, bluebird bio, Inc -... - January 22nd, 2021
- Global Gene Therapy Market Worth $38.41 Million by 2025- Exclusive Report by Fior Markets - PharmiWeb.com - January 22nd, 2021
- Covance boosts Franklin to lead its cell and gene therapy unit - FierceBiotech - January 22nd, 2021
- Explore why Cancer Gene Therapy Market is thriving by 2025 with top key players like Genelux Corporation, Cell Genesys, Advantagene, GenVec,... - January 22nd, 2021
- The global transient protein expression market is expected to reach US$ 983.10 million by 2027 from US$ 660.00 million in 2019 - GlobeNewswire - January 22nd, 2021
- Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism... - January 22nd, 2021
- Cancer Gene Therapy Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 - The Courier - January 22nd, 2021
- Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5... - January 22nd, 2021
- The Global Cancer Gene Therapy Market is expected to grow by $ 2.96 bn during 2021-2025 progressing at a CAGR of 20% during the forecast period -... - January 22nd, 2021
- Gene Therapy Technologies Market Estimated to Experience a Hike in Growth by 2021 2026: Bluebird bio, Adaptimmune, GlaxoSmithKline - KSU | The... - January 22nd, 2021
- Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatment - FierceBiotech - January 22nd, 2021
- Big Boom in Gene Therapy Market Detailed Analysis of Current and Future Industry Figures till 2028 |Novartis AG, Gilead Sciences, Inc., UniQure N.V.,... - January 22nd, 2021
- Gene therapy developed to delay ageing - The Financial Express BD - January 22nd, 2021
- Biogen and ViGeneron to Collaborate on Ophthalmic Gene Therapy Development - JD Supra - January 9th, 2021
- With decades in gene therapy under his belt, Ronald Crystal launches new venture with up to 18 candidates in the pipe - Endpoints News - January 9th, 2021
- GeneOne to supply plasmid DNA therapy worth $2 million to US - Korea Biomedical Review - January 9th, 2021
- Fujifilm triples down on viral vector manufacturing with new $40M Boston site - FiercePharma - January 9th, 2021
- REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne... - January 9th, 2021
- Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin - Science Advances - January 9th, 2021
- Chinese researchers discover new anti-aging gene therapy - The Star Online - January 9th, 2021
- Engineered stem cells that evade immune detection could boost cell therapy and I-O - FierceBiotech - January 9th, 2021
- article image Advances in gene therapy to help paralysis - Digital Journal - January 9th, 2021
- Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell... - January 9th, 2021
- AllStripes Announces Collaboration with Taysha Gene Therapies for SURF1-Associated Leigh Syndrome Program - Business Wire - January 9th, 2021
- Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire - January 9th, 2021
- Global Cell and Gene Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - GlobeNewswire - January 9th, 2021
- Mana joins the hectic fight against solid tumors with an 'off-the-shelf' candidate angling for an IND this year - Endpoints News - January 9th, 2021
- Dewpoint forges another big pharma partnership and a potential rivalry - BioPharma Dive - January 9th, 2021
- IsoPlexis scores big backer for personalized protein 'barcodes' as Perceptive jumps on board new funding round - Endpoints News - January 9th, 2021
- Global Soft Tissue Repair Market- Featuring 3M Co., Arthrex Inc., and Baxter International Inc. Among Others - Business Wire - January 9th, 2021
- Looking to solve the solid tumor puzzle box, Carisma aims to take 'CAR-M' groundbreaker into early-stage trial - Endpoints News - January 9th, 2021
- DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash - Endpoints News - January 9th, 2021
- Study: Too few with high blood pressure tested for hormone disorder - UPI News - December 30th, 2020
- These Families Raised Millions To Fund Treatment For Their Kids' Genetic Disorders. It Hasn't Happened. - KCUR - December 26th, 2020
- Taysha Gene Therapies Announces Queen's University's Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of... - December 26th, 2020
- After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream - PMLiVE - December 26th, 2020
- Regenerative Medicine in Pharma 2020 - Opportunities, Challenges, and Unmet Needs - GlobeNewswire - December 26th, 2020
- Gene Therapy for Rare Disease Market Prospects Pinpoint Higher Traction from Developed Nations during 2020-2026 | Coherent Market Insights | Kite... - December 26th, 2020
- Gene Therapy Market Regions, Type and Application, Futuristic Study - Factory Gate - December 26th, 2020
- News briefing: Merck buys into A2's T cell therapy platform; Small Soligenix reports PhIII fail in head and neck cancer - Endpoints News - December 26th, 2020
- Biopharma Money on the Move: December 16-22 - BioSpace - December 26th, 2020
- Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas -... - December 26th, 2020
- Ocugen Establishes Vaccine Scientific Advisory BoardLeading experts to evaluate the clinical and regulatory path to approval in the US market of... - December 26th, 2020
- Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in... - December 26th, 2020
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases - Business... - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- The next generation of gene therapy for rare diseases forges ahead as developers weather hurdles - FierceBiotech - December 19th, 2020
- Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid... - December 19th, 2020
- Repurposing a proven gene therapy approach to treat, prevent COVID-19 - Penn Today - December 19th, 2020
- Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies - BioSpace - December 19th, 2020
- Technical Report on Gene Therapy in Oncology Market 2021 - LionLowdown - December 19th, 2020
- Biopharma Money on the Move: December 9-15 - BioSpace - December 19th, 2020
- Global Gene Expression Market Analysis and Forecasts - A $6.78 Billion Market by 2027 - PRNewswire - December 19th, 2020
- Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds - Forbes - December 17th, 2020
- Lilly scores gene therapy programme in $1bn Prevail Therapeutics acquisition deal - PMLiVE - December 17th, 2020
- Gene Therapy in One Eye Improves Vision in Both Eyes - The Scientist - December 17th, 2020
- Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -... - December 17th, 2020
- Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA) - Canada NewsWire - December 17th, 2020
- Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,... - December 17th, 2020
- Passage Bio Invests In Gene Therapy Manufacturing R&D Site - Contract Pharma - December 17th, 2020
- Experimental Therapy Injected in One Eye Unexpectedly Improves Vision in The Other - ScienceAlert - December 17th, 2020
- After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic - Endpoints News - December 17th, 2020
- They thought their gene therapy failed. Instead, it spawned a medical mystery - Endpoints News - December 17th, 2020
- Cell And Gene Therapy Market Trends, Growth, Size, Analysis and Forecast by 2024 with Top Players: JW CreaGene,Vericel,Tego Sciences,GC... - December 17th, 2020
- Single gene therapy injection surprisingly boosts vision in both eyes - New Atlas - December 17th, 2020